Trial
NCT05764122
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Ischemic Stroke
Intervention
BIIB131
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-12